DYN
Dyne Therapeutics, Inc.
$16.81
-1.35%
$2.8B
No data for this timeframe.
Vol
Market Cap$2.8B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders8 funds
Inst. Value$424.5M
Inst. Activity3 buys / 0 sells
Insider Activity7B / 27S
Insider Net $-$22.6M
SEC Reports20
Press Releases5
Recent Activity
Jun 8, 2026
Insider
Posner Brian S bought 2,000 shares
Director @ $16.94 ($33.9K)
Jun 8, 2026
short_volume
Short Volume: DYN — 64.0% short (0.4M / 0.6M)
Short: 395,717 | Exempt: 0 | TRF Vol: 618,335 | Short Ratio: 64.0% | Off-exchange volume (dark pool
Jun 5, 2026
Insider
Posner Brian S sold 35,152 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
Stehman-Breen Catherine sold 35,152 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
SEC
Dyne Therapeutics announced full enrollment (71 participants) of the registrational expansion cohort in its Phase 1/2 AC
8-K — Impact 6/10
Jun 3, 2026
Press
Dyne Therapeutics announced completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE tri
Impact 5/10
May 13, 2026
SEC
Director John Cox filed a Form 144 notice of intent to sell 3,311 shares of Dyne Therapeutics common stock, valued at ap
144 — Impact 2/10
May 13, 2026
SEC
Erick Lucera, an officer of Dyne Therapeutics, filed a Form 144 notice of intent to sell 1,448 shares of common stock, w
144 — Impact 2/10
Price Targets
$38.25
+113.4% upside
Strong Buy
Current $17.92
Low $17.00
Median $39.50
High $50.00
16 analysts
$17.00
$50.00
Analyst Ratings
7Strong Buy
10Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
| May 13, 2026 | Bernstein | MAINTAIN | Market Perform → Market Perform |
| Mar 9, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 3, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| Mar 3, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.75 ▲ +6.0% | $-0.84 — $-0.62 | 23% YoY | 11 |
| Next Q | $-0.76 ▲ +4.4% | $-0.90 — $-0.60 | 0% YoY | 11 |
| Current FY | $-3.08 ▲ +3.4% | $-3.46 — $-2.78 | 11% YoY | 13 |
| Next FY | $-2.98 ▲ +1.8% | $-3.89 — $-2.27 | 3% YoY | 12 |
Latest Reports
BULLISH
8-K
6/10
Dyne Therapeutics announced full enrollment (71 participants) of the registrational expansion cohort in its Phase 1/2 AC
Jun 3, 2026
NEUTRAL
Press
5/10
Dyne Therapeutics announced completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE tri
Jun 3, 2026
NEUTRAL
144
2/10
Director John Cox filed a Form 144 notice of intent to sell 3,311 shares of Dyne Therapeutics common stock, valued at ap
May 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $219.4M | ADD |
| FMR LLC | $128.5M | TRIM |
| MORGAN STANLEY | $23.7M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $22.5M | ADD |
| BANK OF AMERICA CORP | $17.3M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | Posner Brian | BUY | $33.9K |
| Jun 5, 2026 | Posner Brian | A | $0.00 |
| Jun 5, 2026 | Stehman-Breen Catherine | A | $0.00 |
| Jun 5, 2026 | Incerti Carlo | A | $0.00 |
| Jun 5, 2026 | Kersten Dirk | A | $0.00 |
8 institutional holders with $424.5M total value (21,701,087 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 11,215,565 | $219.4M | 51.7% | ADD +27.6% |
| 2 | FMR LLC | 6,569,921 | $128.5M | 30.3% | TRIM -35.0% |
| 3 | MORGAN STANLEY | 1,213,559 | $23.7M | 5.6% | ADD +84.7% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,151,325 | $22.5M | 5.3% | ADD +35.2% |
| 5 | BANK OF AMERICA CORP /DE/ | 882,922 | $17.3M | 4.1% | ADD +48.1% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 470,645 | $9.2M | 2.2% | ADD +36.2% |
| 7 | WELLS FARGO & COMPANY/MN | 147,831 | $2.9M | 0.7% | ADD +69.7% |
| 8 | NORGES BANK | 49,319 | $964.7K | 0.2% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 345,500 | 470,645 | +36.2% | $9.2M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 87,121 | 147,831 | +69.7% | $2.9M | 2025-Q4 |
| NORGES BANK | NEW | — | 49,319 | — | $964.7K | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 7,651,157 | 9,760,414 | +27.6% | $123.5M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 745,071 | 1,007,194 | +35.2% | $12.7M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 513,801 | 761,112 | +48.1% | $9.6M | 2025-Q3 |
| UBS Group AG | DOUBLED | 121,792 | 349,388 | +186.9% | $4.4M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 345,500 | — | $4.4M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 56,705 | 87,121 | +53.6% | $1.1M | 2025-Q3 |
| NORGES BANK | EXIT | 49,319 | 0 | -100.0% | $0.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 269,976 | 513,801 | +90.3% | $4.9M | 2025-Q2 |
| UBS Group AG | TRIM | 357,754 | 121,792 | -66.0% | $1.2M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 40,158 | 56,705 | +41.2% | $539.8K | 2025-Q2 |
| NORGES BANK | NEW | — | 49,319 | — | $469.5K | 2025-Q2 |
| FMR LLC | TRIM | 7,996,931 | 5,195,294 | -35.0% | $54.3M | 2025-Q1 |
| MORGAN STANLEY | ADD | 753,593 | 1,391,587 | +84.7% | $14.6M | 2025-Q1 |
| UBS Group AG | TRIM | 540,112 | 357,754 | -33.8% | $3.7M | 2025-Q1 |
| NORGES BANK | EXIT | 950,104 | 0 | -100.0% | $0.00 | 2025-Q1 |
| NORGES BANK | DOUBLED | 432,327 | 950,104 | +119.8% | $22.4M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 1,053,262 | 753,593 | -28.5% | $17.8M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 25,077 | 38,754 | +54.5% | $913.0K | 2024-Q4 |
| MORGAN STANLEY | ADD | 559,052 | 1,053,262 | +88.4% | $37.8M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 648,652 | — | $23.3M | 2024-Q3 |
11 unique insiders with 34 transactions. Net insider value: -$22.6M ($274.8K bought, $22.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Posner Brian S | Director | BUY | 2,000 | $16.94 | $33.9K |
| Jun 5, 2026 | Posner Brian S | Director | A | 35,152 | $0.00 | $0.00 |
| Jun 5, 2026 | Stehman-Breen Catherine | Director | A | 35,152 | $0.00 | $0.00 |
| Jun 5, 2026 | Incerti Carlo | Director | A | 35,152 | $0.00 | $0.00 |
| Jun 5, 2026 | Kersten Dirk | Director | A | 35,152 | $0.00 | $0.00 |
| Jun 5, 2026 | Rhodes Jason P | Director | A | 35,152 | $0.00 | $0.00 |
| Jun 5, 2026 | HURWITZ EDWARD | Director | A | 35,152 | $0.00 | $0.00 |
| Jun 3, 2026 | Posner Brian S | Director | BUY | 2,500 | $17.48 | $43.7K |
| May 26, 2026 | Posner Brian S | Director | BUY | 2,000 | $18.21 | $36.4K |
| May 20, 2026 | Posner Brian S | Director | BUY | 2,500 | $17.12 | $42.8K |
| May 13, 2026 | Lucera Erick | Chief Financial Officer | SELL | 1,448 | $18.36 | $26.6K |
| May 13, 2026 | Cox John | CEO & President | SELL | 3,311 | $18.36 | $60.8K |
| May 13, 2026 | Kerr Douglas | Chief Medical Officer | SELL | 1,564 | $18.36 | $28.7K |
| May 13, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | SELL | 228 | $18.36 | $4.2K |
| May 6, 2026 | Rhodes Jason P | Director | SELL | 21,926 | $18.18 | $398.6K |
| May 5, 2026 | Rhodes Jason P | Director | SELL | 3,056 | $18.03 | $55.1K |
| May 4, 2026 | Rhodes Jason P | Director | SELL | 3,136 | $18.00 | $56.4K |
| Apr 28, 2026 | Rhodes Jason P | Director | SELL | 59,870 | $18.38 | $1.1M |
| Apr 27, 2026 | Rhodes Jason P | Director | SELL | 45,709 | $18.15 | $829.6K |
| Apr 24, 2026 | Rhodes Jason P | Director | SELL | 36,345 | $18.48 | $671.7K |
| Apr 24, 2026 | Lubner David Charles | Director | G | 53,625 | $0.00 | $0.00 |
| Apr 23, 2026 | Rhodes Jason P | Director | SELL | 19,261 | $19.19 | $369.6K |
| Apr 22, 2026 | Kersten Dirk | Director | SELL | 2,652 | $20.00 | $53.0K |
| Apr 22, 2026 | Rhodes Jason P | Director | SELL | 75,866 | $19.68 | $1.5M |
| Apr 21, 2026 | Kersten Dirk | Director | SELL | 8,300 | $20.01 | $166.1K |
| Apr 21, 2026 | Rhodes Jason P | Director | SELL | 71,499 | $19.51 | $1.4M |
| Apr 20, 2026 | Kersten Dirk | Director | SELL | 125,274 | $20.07 | $2.5M |
| Apr 20, 2026 | Rhodes Jason P | Director | SELL | 71,676 | $20.06 | $1.4M |
| Apr 17, 2026 | Kersten Dirk | Director | SELL | 211,974 | $20.29 | $4.3M |
| Apr 16, 2026 | Kersten Dirk | Director | SELL | 11,116 | $21.10 | $234.6K |
| Apr 15, 2026 | Kersten Dirk | Director | SELL | 81,840 | $20.27 | $1.7M |
| Apr 1, 2026 | Lucera Erick | Chief Financial Officer | SELL | 5,727 | $18.64 | $106.8K |
| Mar 30, 2026 | Posner Brian S | Director | BUY | 2,000 | $17.08 | $34.2K |
| Mar 11, 2026 | Posner Brian S | Director | BUY | 2,000 | $19.35 | $38.7K |
| Mar 11, 2026 | Kersten Dirk | Director | SELL | 129,672 | $19.52 | $2.5M |
| Mar 10, 2026 | Kersten Dirk | Director | SELL | 9,482 | $18.21 | $172.7K |
| Mar 9, 2026 | Kersten Dirk | Director | SELL | 177,690 | $17.72 | $3.1M |
| Mar 6, 2026 | Posner Brian S | Director | BUY | 3,000 | $15.06 | $45.2K |
| Mar 5, 2026 | Cox John | CEO & President | SELL | 2,732 | $14.90 | $40.7K |
| Mar 5, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | SELL | 148 | $14.90 | $2.2K |
| Mar 5, 2026 | Kerr Douglas | Chief Medical Officer | SELL | 904 | $14.90 | $13.5K |
| Feb 12, 2026 | Kerr Douglas | Chief Medical Officer | A | 85,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Kerr Douglas | Chief Medical Officer | A | 130,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Cox John | CEO & President | A | 180,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Cox John | CEO & President | A | 285,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | A | 60,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | A | 90,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Lucera Erick | Chief Financial Officer | A | 65,000 | $0.00 | $0.00 |
| Feb 12, 2026 | Lucera Erick | Chief Financial Officer | A | 105,000 | $0.00 | $0.00 |
20 SEC filing reports analyzed. Sentiment: 1 bullish, 5 bearish, 0 mixed, 14 neutral. Avg impact: 3.5/10.
BULLISH
8-K
6/10
Dyne Therapeutics announced full enrollment (71 participants) of the registrational expansion cohort
Jun 3, 2026
NEUTRAL
144
2/10
Director John Cox filed a Form 144 notice of intent to sell 3,311 shares of Dyne Therapeutics common
May 13, 2026
NEUTRAL
144
2/10
Erick Lucera, an officer of Dyne Therapeutics, filed a Form 144 notice of intent to sell 1,448 share
May 13, 2026
NEUTRAL
8-K
5/10
Dyne Therapeutics reported Q1 2026 net loss of $120.9M ($0.73/share), wider than the $115.4M loss in
May 11, 2026
NEUTRAL
144
2/10
Atlas Venture Fund XI, L.P. filed a Form 144 indicating intent to sell 43,621 shares of Dyne Therape
May 6, 2026
NEUTRAL
144
2/10
Atlas Venture Associates XI, L.P., a major venture capital shareholder, filed a Form 144 indicating
May 6, 2026
NEUTRAL
144
2/10
Atlas Venture Opportunity Fund I, L.P., a major venture investor, filed a Form 144 indicating intent
May 4, 2026
NEUTRAL
144
2/10
Atlas Venture Fund XI, L.P., a major shareholder, filed a Form 144 to sell 6,241 shares of Dyne Ther
May 4, 2026
NEUTRAL
144
2/10
Atlas Venture Associates XI, L.P. filed a Form 144 to sell 61 shares of Dyne Therapeutics, with an e
May 4, 2026
NEUTRAL
CLUSTER
3/10
Two Dyne Therapeutics directors sold a total of ~$1.15M in stock over a 7-day window, with Director
Apr 30, 2026
NEUTRAL
CLUSTER
4/10
Director Jason P. Rhodes sold $3.4M worth of DYN shares over a five-day window, with total insider s
Apr 28, 2026
BEARISH
144
5/10
Atlas Venture Opportunity Fund I, L.P., a major venture capital backer of Dyne Therapeutics, filed a
Apr 28, 2026
NEUTRAL
CLUSTER
2/10
Two Dyne Therapeutics directors, Jason Rhodes and Dirk Kersten, sold a combined $423K in open-market
Apr 27, 2026
BEARISH
144
6/10
Three institutional investors affiliated with Atlas Venture—Atlas Venture Associates XI, L.P., Atlas
Apr 24, 2026
NEUTRAL
DEFA14A
3/10
Dyne Therapeutics has filed its definitive proxy statement for the upcoming annual shareholder meeti
Apr 23, 2026
BEARISH
CLUSTER
6/10
Two directors at Dyne Therapeutics (DYN) sold over $11.4 million in shares over the past 7 days, inc
Apr 23, 2026
NEUTRAL
144
2/10
Atlas Venture Associates XI, L.P., a shareholder of Dyne Therapeutics, filed a Form 144 notifying in
Apr 20, 2026
BEARISH
144
6/10
Two affiliated venture funds, Atlas Venture Fund XI and Atlas Venture Opportunity Fund I, filed Form
Apr 20, 2026
NEUTRAL
CLUSTER
3/10
A mixed insider trading cluster at Dyne Therapeutics shows CFO Erick Lucera selling $107K in shares
Apr 3, 2026
BEARISH
144
5/10
Lucera Erick, an officer of Dyne Therapeutics, filed a Form 144 to notify intent to sell up to 57,27
Apr 1, 2026
NEUTRAL
5/10
Dyne Therapeutics announced completion of enrollment in the registrational expansion cohort of the P
Jun 3, 2026
NEUTRAL
2/10
Dyne Therapeutics granted inducement equity awards to 17 newly hired employees, consisting of stock
May 20, 2026
BULLISH
7/10
Dyne Therapeutics initiated the Phase 3 FORZETTO trial of z-rostudirsen (DYNE-251) in Duchenne muscu
May 20, 2026
BULLISH
8/10
Dyne Therapeutics announced 24-month data from its Phase 1/2 DELIVER trial showing sustained functio
Mar 8, 2026
BULLISH
8/10
Dyne Therapeutics reported positive topline results from the Phase 1/2 DELIVER trial of z-rostudirse
Mar 2, 2026
Current analyst consensus: Strong Buy (85% buy). Based on 20 analysts: 7 strong buy, 10 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$38.25 mean target
+113.4% upside
Strong Buy (1.44)
$17.00 Low
$50.00 High
| Metric | Value |
|---|---|
| Current Price | $17.92 |
| Target Low | $17.00 |
| Target Mean | $38.25 |
| Target Median | $39.50 |
| Target High | $50.00 |
| # Analysts | 16 |
| Recommendation | Strong Buy (1.44) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.75 | $-0.84 | $-0.62 | 22.8% | +6.0% | 5↑ 5↓ | $0.0B | 0.0% | 11 |
| Next Q 2026-09-30 |
$-0.76 | $-0.90 | $-0.60 | 0.0% | +4.4% | 5↑ 5↓ | $0.0B | 0.0% | 11 |
| Current FY 2026-12-31 |
$-3.08 | $-3.46 | $-2.78 | 11.1% | +3.4% | 7↑ 6↓ | $0.0B | 0.0% | 13 |
| Next FY 2027-12-31 |
$-2.98 | $-3.89 | $-2.27 | 3.3% | +1.8% | 4↑ 7↓ | $0.1B | 0.0% | 12 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.749 | |
| 7d ago | $-0.749 | |
| 30d ago | $-0.797 | +0.048 |
| 60d ago | $-0.797 | +0.048 |
| 90d ago | $-0.794 | +0.045 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| May 13, 2026 | Bernstein | MAINTAIN | Market Perform | Market Perform |
| Mar 9, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 3, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Dec 15, 2025 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 10 | 3 | 0 | 0 | 85% | |
| May 1, 2026 | 7 | 10 | 3 | 0 | 0 | 85% | |
| Apr 1, 2026 | 7 | 10 | 3 | 0 | 0 | 85% | |
| Mar 1, 2026 | 7 | 10 | 3 | 0 | 0 | 85% | |
| Feb 1, 2026 | 7 | 10 | 3 | 0 | 0 | 85% | |
| Jan 1, 2026 | 7 | 10 | 3 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 8, 2026
short_volume
Short Volume: DYN — 64.0% short (0.4M / 0.6M)
Short: 395,717 | Exempt: 0 | TRF Vol: 618,335 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: DYN — 56.2% short (0.4M / 0.7M)
Short: 371,592 | Exempt: 986 | TRF Vol: 661,139 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
fda
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
<p align="center"><em>- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - </em></p>
Jun 2, 2026
short_volume
Short Volume: DYN — 69.1% short (0.4M / 0.6M)
Short: 446,219 | Exempt: 0 | TRF Vol: 645,445 | Short Ratio: 69.1% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: DYN — 76.4% short (0.4M / 0.6M)
Short: 434,685 | Exempt: 0 | TRF Vol: 569,161 | Short Ratio: 76.4% | Off-exchange volume (dark pool + OTC)
May 26, 2026
other
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
<p align="center"><em>- Submission for Accelerated Approval based on dystrophin as a surrogate endpoint -</em></p>
May 26, 2026
short_volume
Short Volume: DYN — 84.5% short (0.5M / 0.6M)
Short: 546,682 | Exempt: 0 | TRF Vol: 647,191 | Short Ratio: 84.5% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: DYN — 87.3% short (0.5M / 0.6M)
Short: 490,888 | Exempt: 74 | TRF Vol: 562,518 | Short Ratio: 87.3% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: DYN — 82.0% short (0.5M / 0.6M)
Short: 452,861 | Exempt: 7,867 | TRF Vol: 551,987 | Short Ratio: 82.0% | Off-exchange volume (dark pool + OTC)
May 20, 2026
activist
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=yvxOg06WRLoiHP67ePX0j327M-HARlS_VL1qtfxsoAH-
May 20, 2026
fda
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
<p align="center"><em>- 72-week trial will enroll approximately 90 participants; first site now open for enrollment -</em></p>
May 20, 2026
short_volume
Short Volume: DYN — 83.5% short (0.5M / 0.6M)
Short: 474,982 | Exempt: 7,053 | TRF Vol: 568,856 | Short Ratio: 83.5% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: DYN — 64.8% short (0.3M / 0.5M)
Short: 326,011 | Exempt: 8,303 | TRF Vol: 502,950 | Short Ratio: 64.8% | Off-exchange volume (dark pool + OTC)
May 13, 2026
other
Dyne Therapeutics to Participate in Upcoming Investor Conferences
<p align="left">WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=C-5t0aGnjkHMrOVYKUMNDCAssDb9bzr
May 11, 2026
earnings
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
<p align="center"><em>- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and poten